Abstract
Purpose of review:
Chronic pulmonary aspergillosis (CPA) is a serious long term fungal disease of the lung with a worldwide prevalence. Treatment of CPA is not straightforward given the often-multiple associated co-morbidities, complex clinical picture, drug interactions, toxicities and intolerances.
Recent findings:
First line treatment is oral itraconazole or voriconazole. In the event of intolerance or toxicity; patients may be swapped from itraconazole to voriconazole or vice versa. In the event of resistance or further intolerance; third line treatment with posaconazole could be initiated. In those with pan-azole resistance short term courses of intravenous liposomal amphotericin B or micafungin are fourth line therapy, keeping in mind the nephrotoxic effects of amphotericin B.
Summary:
The available evidence for current treatments in CPA is limited and based mostly on retrospective cohort studies. There is a real need to raise awareness of this devastating disease to enable early treatment as well as prospective drug trials and studies to identify potential patient factors that correlate with progression, severity and overall outcomes in order to target future therapies.
Chronic pulmonary aspergillosis (CPA) is a serious long term fungal disease of the lung with a worldwide prevalence. Treatment of CPA is not straightforward given the often-multiple associated co-morbidities, complex clinical picture, drug interactions, toxicities and intolerances.
Recent findings:
First line treatment is oral itraconazole or voriconazole. In the event of intolerance or toxicity; patients may be swapped from itraconazole to voriconazole or vice versa. In the event of resistance or further intolerance; third line treatment with posaconazole could be initiated. In those with pan-azole resistance short term courses of intravenous liposomal amphotericin B or micafungin are fourth line therapy, keeping in mind the nephrotoxic effects of amphotericin B.
Summary:
The available evidence for current treatments in CPA is limited and based mostly on retrospective cohort studies. There is a real need to raise awareness of this devastating disease to enable early treatment as well as prospective drug trials and studies to identify potential patient factors that correlate with progression, severity and overall outcomes in order to target future therapies.
| Original language | English |
|---|---|
| Journal | Current Infectious Disease Reports |
| Publication status | Accepted/In press - 27 Jul 2017 |